FDA Oncologic Drug Committee Agrees That “Kitty Fight” With NCI Should Be Negotiated
In Brief: NCI Tells Cooperative Groups To Submit applications For Extra Multimodality Funds
FDA Delays NDA On BCNU, But New Drug Seminar Still Scheduled
Proposed Guidelines For Clinical Tests Of Oncologic Drugs
UCLA, NYU, Ohio States Must Wait Longer For Comprehensive Status
Contact Planned To Encourage Insurers To Reimburse For Cancer Screening
Rosemond Asks Ban On High Tar, Nicotine Cigarettes
Trending Stories
- OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- Peter F. Garrett to people with cancer: Your story has power
- What NHS-Galleri taught us—and what it didn’t
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”









